TheranosticTrials.org

Clinical Trial · NCT06586047

Breast Cancer PSMA PET

Overview

The purpose of this research is to determine the expression of Prostate Specific Membrane Antigen(PSMA) in metastatic Triple Negative Breast Cancer (TNBC) patients using Fludeoxyglucose F18 (FDG) PET/CT as the gold standard. The investigators hypothesize that most lesions in metastatic TNBC are PSMA-avid; and thus PSMA-based radionuclide therapy can be a valid treatment option for TNBC, and clinical trials can be designed for this purpose. Thirty metastatic TNBC patients will be enrolled and will be on the study for maximum of 4 weeks.

Sponsor

University of Iowa

Phase

Early Phase 1

Contacts

Elina Shrestha (CONTACT)

eshrestha@uiowa.edu

319 335 0114

Ahmad Shariftabrizi, M.D. (CONTACT)

ashariftabrizi@uiowa.edu

319-887-4942

ClinicalTrials.gov

NCT06586047

Drug / Compound

FDG

Isotope(s):
Target(s):
  • Glucose Transport
Ligand Class: Small Molecules

DCFPyL

Isotope(s):
Target(s):
  • PSMA
Ligand Class: Small Molecules

Eligibility

Inclusion

  • Patient should have FDG positive metastatic lesions on the initial PET/CT scan performed in this study to be further included.
  • Patients in distantly metastatic TNBC based on the initial diagnosis biopsy.

Exclusion

Exclusion criteria not yet provided.